REFERENCES
- Bartlett N., Koczwara B. Control of nausea and vomiting after chemotherapy: what is the evidence?. Intern. Med. J. 2002; 32: 401–407
- Mantovani G., Maccio A., Bianchi A., Curreli L., Ghiani M., Proto E., Santona M C. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996; 77: 941–948
- Barrajon E., de las Penas R. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron a cost-benefit analysis. Support Care Cancer 2000; 8: 323–333
- Forni C., Ferrari S., Loro L., Mazzei T., Beghelli C., et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 2000; 8: 131–133
- Lacerda J. F., Martins C., Carmo J. A., Lourenco M. F., Araujo Pereira M. E., Rodrigues A., Juncal C., Lacerda J. M. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting. Transplant Proc. 2000; 32: 2680–2681
- Dixon C. M., Colthup P. V., Serabjit-Singh C. J., Kerr B. M., Boehlert C. C., Park G. R., Tarbit M. H. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab. Dispos. 1995; 23: 1225–1230
- Sanwald P., David M., Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. comparison with other indole-containing 5-HT3 antagonists. Drug Metab. Dispos. 1996; 24: 602–609
- Blower P. R. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. J. Cancer 2002; 8: 405–414
- Oge A., Alkis N., Oge O., Kartum A. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. J Chemother. 2000; 12: 105–108
- Hesketh P. J., Gralla R. J., du Bois A., Tonato M. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 1998; 6: 221–227
- Republic o f. Turkey Ministry of Health, Available at www.saglik.gov.tr (accessed July 15, 2004).
- Gralla R. J., Osoba D., Kris M. G., Kirkbride P., Hesketh P. J., et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 1999; 17: 2971–2994
- Koeller J. M., Aapro M. S., Gralla R. J., Grunberg S. M., Hesketh P. J., Kris M. G., Clark-Snow R. A. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10: 519–522
- Yalcin S., Tekuzman G., Baltali E., Ozisik Y., Barista I. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am. J. Clin. Oncol. 1999; 22: 94–96
- Gray G. W., McLellan T. M., Ducharme M. B. Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat. Space Environ. Med. 1996; 67: 759–761
- Ruff P., Paska W., Goedhals L., Pouillart P., Riviere A., et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994; 51: 113–118